Zoster Vaccine, Recombinant, Adjuvanted (Shingrix)
Treatment for Varicella And Herpes Zoster
Typical Dosage: 0.5 mL IM, 2 doses 2-6 months apart
Effectiveness
95%
Safety Score
85%
Clinical Trials
9
Participants
40K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe
Treatment Details
Dosage Range
0.5 mL IM, 2 doses 2-6 months apart
Time to Effect
1 month after second dose
Treatment Duration
Two-dose series, protection >10 years
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100000(Treat 100000 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$320
Monitoring:$100
Side Effect Mgmt:$5
Total Annual:$42.5
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$24,000/QALY
QALYs Gained
0.057
Comparison vs Zostavax
Cost Difference
+$125/year
More expensive
QALY Difference
+0.04 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Physician Visit Cost
$25/year
Time Cost
$6/year
Travel + wait time
Insurance Admin Cost
$1/year
Prior auth, claims
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWZoster Vaccine, Recombinant, Adjuvanted (Shingrix) Outcomes
for Varicella And Herpes Zoster
Efficacy Outcomes
Overall Effectiveness
+95%
Common Side Effects
Injection site pain
+80%
Myalgia
+40%
Fatigue
+40%
Headache
+35%
Fever
+20%
Sources:
Active Clinical Trials
4 active trials recruiting for Zoster Vaccine, Recombinant, Adjuvanted (Shingrix) in Varicella And Herpes Zoster
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
NCT05580458RECRUITINGPHASE1, PHASE2
225 participants
INTERVENTIONAL
Bethesda, United States
Started: Mar 13, 2023
Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
NCT06874842RECRUITINGPHASE1
92 participants
INTERVENTIONAL
Meizhou, China
Started: Mar 13, 2025
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older
NCT07311148ACTIVE NOT RECRUITINGPHASE2
840 participants
INTERVENTIONAL
Hengyang, China
Started: Oct 23, 2025
Shingrix in Renal Transplant Recipients
NCT04128189RECRUITINGPHASE3
132 participants
INTERVENTIONAL
Aurora, United States +3 more
Started: Mar 2, 2023
Completed Clinical Trials
6 completed trials for Zoster Vaccine, Recombinant, Adjuvanted (Shingrix) in Varicella And Herpes Zoster
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
NCT05856084COMPLETEDPHASE2
924 participants
INTERVENTIONAL
Xinxiang, China
Started: May 7, 2023
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
NCT03702231COMPLETEDPHASE2
116 participants
INTERVENTIONAL
Bethesda, United States
Started: Dec 7, 2018
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
NCT05636436COMPLETEDPHASE1
132 participants
INTERVENTIONAL
Xinxiang, China
Started: Dec 7, 2022
A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years
NCT05991427COMPLETEDPHASE1
65 participants
INTERVENTIONAL
Halifax, Canada
Started: Nov 7, 2023
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
NCT04523246COMPLETEDEARLY_PHASE1
217 participants
INTERVENTIONAL
Oklahoma City, United States
Started: Sep 1, 2020
Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
NCT03771157COMPLETEDEARLY_PHASE1
33 participants
INTERVENTIONAL
Rochester, United States
Started: Feb 1, 2019